Skip to main content
Premium Trial:

Request an Annual Quote

Primate Data on Tekmira Marburg Infection Drug Published

Premium

NEW YORK (GenomeWeb) – Tekmira Pharmaceuticals this week announced the publication of data showing that siRNAs targeting the Marburg virus and formulated with its proprietary lipid nanoparticles can completely protect non-human primates from infection.

The findings were published in Science Translational Medicine, and were previously presented by the company in April at the 6th International Symposium of Filoviruses.

According to the study, the animals were infected with the virus, then given 0.5 mg/kg doses of the drug — called TKM-Marburg — once a day for seven days 72 hours later. All of the treated primates survived.

Previously, Tekmira and collaborators at the University of Texas Medical Branch showed that TKM-Marburg could offer complete protection from lethal Marburg infection when given 24 hours and 48 hours after exposure.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.